MedTrace Logo

Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas

NCT00785798 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2022-04-04

Study results available
· View outcomes & findings →

Summary

The study will be a dose-finding, phase I study of the combination of vorinostat and PLD in patients with advanced lymphoma refractory to at least one prior systemic therapy.

Conditions

  • Relapsed Lymphomas
  • Refractory Lymphomas

Interventions

DRUG

Vorinostat

200mg to 400 mg twice daily on days 1-7

DRUG

Pegylated Liposomal Doxorubicin (PLD), Doxil

IV 30mg/m2 on day 3 of a 21-day cycle

Sponsors & Collaborators

Principal Investigators

  • Francine Foss, MD · Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00785798 on ClinicalTrials.gov